Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

Sanofi Earns Price Target Cut After Stopping Breast Cancer Drug Trial

Published 17/08/2022, 19:28
Sanofi Earns Price Target Cut After Stopping Breast Cancer Drug Trial
SASY
-
SNY
-
TGTB34
-
AVEPp
-

  • Sanofi (EPA:SASY) SA (NASDAQ: SNY) discontinued the development of its oral SERD amcenestrant following a negative interim analysis of the AMEERA-5 trial in front-line ER+ metastatic breast cancer in combination with Pfizer Inc's (NYSE: NYSE:PFE) Ibrance.
  • The analyst lowered the price target to $52 and maintained the Outperform rating.
  • Related content: Sanofi Ends Development Of Breast Cancer Drug Amcenestrant After Trial Failure.
  • SVB previously expected a 2025 launch for amcenestrant and estimated €1.6 billion 2030E sales. Removing amcenestrant did not change 2022-2023E revenue and EPS estimates.
  • Though 2025-2031E revenue estimates decreased by 0-3%, EPS estimates decreased by 1-7%.
  • The analyst says that after the recent partial clinical hold of tolebrutinib for multiple sclerosis due to liver tox risks, the amcenestrant discontinuation is negative for sentiment for the company's R&D productivity and topline growth prospects.
  • Price Action: SNY shares are down 7.10% at $41.63 on the last check Wednesday.
Sep 2021SVB LeerinkUpgradesMarket PerformOutperform
Jan 2021 Deutsche Bank (ETR:DBKGn)Initiates Coverage OnSell
Mar 2020Goldman Sachs (NYSE:GS)UpgradesNeutralBuy

View the Latest Analyst Ratings

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.